Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.36)
# 1,011
Out of 4,944 analysts
102
Total ratings
46.51%
Success rate
3.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $3.03 | +362.05% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $28.97 | +341.84% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $395.92 | +3.81% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $8.76 | +116.89% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $432.52 | -4.05% | 9 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $3.09 | +223.62% | 9 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $92 → $105 | $97.86 | +7.30% | 8 | Jul 18, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $74 → $54 | $11.00 | +390.91% | 6 | Jun 3, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $53 → $52 | $44.64 | +16.49% | 3 | May 16, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $68 → $66 | $19.21 | +243.57% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 | $6.61 | +1,261.57% | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $0.86 | +596.78% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 | $6.38 | +3,975.24% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $20.40 | +635.29% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $58.30 | +44.08% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $120.14 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $4.45 | +5,293.26% | 4 | Jul 23, 2019 |
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.03
Upside: +362.05%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $28.97
Upside: +341.84%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $395.92
Upside: +3.81%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $8.76
Upside: +116.89%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $432.52
Upside: -4.05%
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.09
Upside: +223.62%
Rhythm Pharmaceuticals
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $97.86
Upside: +7.30%
Intellia Therapeutics
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $11.00
Upside: +390.91%
Palvella Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $53 → $52
Current: $44.64
Upside: +16.49%
Arcturus Therapeutics Holdings
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $19.21
Upside: +243.57%
Mar 17, 2025
Maintains: Buy
Price Target: $90
Current: $6.61
Upside: +1,261.57%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.86
Upside: +596.78%
Nov 14, 2024
Maintains: Buy
Price Target: $260
Current: $6.38
Upside: +3,975.24%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $20.40
Upside: +635.29%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $58.30
Upside: +44.08%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $120.14
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $4.45
Upside: +5,293.26%